Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

Signet Ring Cell Carcinoma of the Lung: A Diagnostic Pitfall in Pregnancy.

Danzinger S, Köstler WJ, Funovics M, Herac M, Müllauer L, Prosch H, Kölbl H.

Case Rep Obstet Gynecol. 2019 Jun 12;2019:9461579. doi: 10.1155/2019/9461579. eCollection 2019.

2.

Contralateral prophylactic mastectomy in women with breast cancer without a family history or genetic predisposition : Consensus statement from the Austrian Gynecologic Oncology Working Group of the Austrian Society of Obstetrics and Gynecology.

Bjelic-Radisic V, Singer C, Tamussino K, Kölbl H, Petru E, Volgger B, Polterauer S, Oppelt P, Sevelda P, Bogner G, Marth C; Austrian Gynecologic Oncology Working Group.

Wien Klin Wochenschr. 2019 May;131(9-10):233-236. doi: 10.1007/s00508-019-1468-7. Epub 2019 Mar 18.

PMID:
30887224
3.

Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology.

Prager GW, Unseld M, Waneck F, Mader R, Wrba F, Raderer M, Fuereder T, Staber P, Jäger U, Kieler M, Bianconi D, Hoda MA, Baumann L, Reinthaller A, Berger W, Grimm C, Kölbl H, Sibilia M, Müllauer L, Zielinski C.

Oncotarget. 2019 Jan 29;10(9):942-952. doi: 10.18632/oncotarget.26604. eCollection 2019 Jan 29.

4.

Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study.

Polterauer S, Schwameis R, Grimm C, Hillemanns P, Jückstock J, Hilpert F, de Gregorio N, Hasenburg A, Sehouli J, Fürst ST, Strauß HG, Baumann K, Thiel F, Mustea A, Harter P, Wimberger P, Kölbl H, Reinthaller A, Woelber L, Mahner S.

Gynecol Oncol. 2019 May;153(2):286-291. doi: 10.1016/j.ygyno.2019.02.007. Epub 2019 Feb 11.

PMID:
30760408
5.

Joint Guideline of the OEGGG, AGO, AGK and ÖGZ on the Diagnosis and Treatment of Cervical Intraepithelial Neoplasia and Appropriate Procedures When Cytological Specimens Are Unsatisfactory.

Reich O, Braune G, Eppel W, Fiedler T, Graf A, Hefler L, Joura E, Kölbl H, Marth C, Pokieser W, Regitnig P, Reinthaller A, Tamussino K, Widschwendter A, Zeimet A, Kohlberger P.

Geburtshilfe Frauenheilkd. 2018 Dec;78(12):1232-1244. doi: 10.1055/a-0764-4875. Epub 2018 Dec 14.

6.

Co-expressed genes enhance precision of receptor status identification in breast cancer patients.

Kenn M, Cacsire Castillo-Tong D, Singer CF, Cibena M, Kölbl H, Schreiner W.

Breast Cancer Res Treat. 2018 Nov;172(2):313-326. doi: 10.1007/s10549-018-4920-x. Epub 2018 Aug 16.

7.

Prognostic Significance of Pre-treatment Serum C-Reactive Protein Level in Patients with Adenocarcinoma of the Uterine Cervix.

Bodner-Adler B, Kimberger O, Schneidinger C, Kölbl H, Bodner K.

Anticancer Res. 2016 Sep;36(9):4691-6.

PMID:
27630314
8.

Guideline-Based Strategies in the Surgical Treatment of Female Urinary Incontinence: The New Gold Standard is Almost the Same as the Old One.

Viereck V, Bader W, Lobodasch K, Pauli F, Bentler R, Kölbl H.

Geburtshilfe Frauenheilkd. 2016 Aug;76(8):865-868. Review.

9.

Consensus: soy isoflavones as a first-line approach to the treatment of menopausal vasomotor complaints.

Schmidt M, Arjomand-Wölkart K, Birkhäuser MH, Genazzani AR, Gruber DM, Huber J, Kölbl H, Kreft S, Leodolter S, Linsberger D, Metka M, Simoncini T, Vrabic Dezman L.

Gynecol Endocrinol. 2016 Jun;32(6):427-30. doi: 10.3109/09513590.2016.1152240. Epub 2016 Mar 4.

PMID:
26943176
10.

HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK.

Gschwantler-Kaulich D, Grunt TW, Muhr D, Wagner R, Kölbl H, Singer CF.

PLoS One. 2016 Jan 6;11(1):e0146311. doi: 10.1371/journal.pone.0146311. eCollection 2016.

11.

The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial.

Batista JE, Kölbl H, Herschorn S, Rechberger T, Cambronero J, Halaska M, Coppell A, Kaper M, Huang M, Siddiqui E; BEYOND study group.

Ther Adv Urol. 2015 Aug;7(4):167-79. doi: 10.1177/1756287215589250.

12.

Disclosures, conflict of interest, and funding issues in urogynecology articles: a bibliometric study.

Koch M, Riss P, Kölbl H, Umek W, Hanzal E.

Int Urogynecol J. 2015 Oct;26(10):1503-7. doi: 10.1007/s00192-015-2727-4. Epub 2015 May 20.

PMID:
25990207
13.

Correlation of the volume of ectopic pregnancy and MTX therapy outcome: a retrospective cohort study.

Helmy S, Koch M, Kölbl H, Grohmann-Izay B, Solomayer E, Bader Y.

Eur J Obstet Gynecol Reprod Biol. 2015 Jan;184:108-11. doi: 10.1016/j.ejogrb.2014.09.038. Epub 2014 Oct 19.

PMID:
25490001
14.

Cut-off value of initial serum β-hCG level predicting a successful MTX therapy in tubal ectopic pregnancy: a retrospective cohort study.

Helmy S, Bader Y, Pablik E, Tiringer D, Pils S, Laml T, Kölbl H, Koch M.

Eur J Obstet Gynecol Reprod Biol. 2014 Aug;179:175-80. doi: 10.1016/j.ejogrb.2014.05.033. Epub 2014 Jun 2.

PMID:
24956362
15.

Pain perception during outpatient cystoscopy: a prospective controlled study.

Yerlikaya G, Laml T, Elenskaia K, Hanzal E, Kölbl H, Umek W.

Eur J Obstet Gynecol Reprod Biol. 2014 Feb;173:101-5. doi: 10.1016/j.ejogrb.2013.11.007. Epub 2013 Nov 14.

PMID:
24300559
16.

[Current developments and perspectives on the diagnosis and treatment of urinary incontinence and genital prolapse in women].

Naumann G, Kölbl H.

Aktuelle Urol. 2013 May;44(3):201-6. doi: 10.1055/s-0033-1345189. Epub 2013 May 27. Review. German.

PMID:
23712277
17.

Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie.

Emons G, Günthert A, Thiel FC, Camara O, Strauss HG, Breitbach GP, Kölbl H, Reimer T, Finas D, Rensing K; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO).

Gynecol Oncol. 2013 Jun;129(3):495-9. doi: 10.1016/j.ygyno.2013.02.039. Epub 2013 Mar 13.

PMID:
23500091
18.

Transvaginal Ultrasound for Endometrial Carcinoma Screening - Current Evidence-based Data.

Steiner E, Juhasz-Bösz I, Emons G, Kölbl H, Kimmig R, Mallmann P; für die AGO Uterus der DGGG .

Geburtshilfe Frauenheilkd. 2012 Dec;72(12):1088-1091.

19.

Biomarkers in Breast Cancer - An Update.

Schmidt M, Fasching PA, Beckmann MW, Kölbl H.

Geburtshilfe Frauenheilkd. 2012 Sep;72(9):819-832.

20.

Skin-reducing Mastectomy with Primary Implant Reconstruction.

Siggelkow W, Lübbe K, Gade J, Kölbl H, Schmidt M, Böhm D.

Geburtshilfe Frauenheilkd. 2012 Jul;72(7):616-621.

21.

Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach.

Böhm D, Keller K, Pieter J, Boehm N, Wolters D, Siggelkow W, Lebrecht A, Schmidt M, Kölbl H, Pfeiffer N, Grus FH.

Oncol Rep. 2012 Aug;28(2):429-38. doi: 10.3892/or.2012.1849. Epub 2012 Jun 1.

22.

[Comments on sacrocolpoplexy - laparoscopic versus robotic].

Kölbl H.

Urologe A. 2012 May;51(5):705. doi: 10.1007/s00120-012-2893-7. German. No abstract available.

PMID:
22526192
23.

A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis.

Mahner S, Oskay-Özcelik G, Heidrich-Lorsbach E, Fuxius S, Sommer H, Klare P, Belau A, Ruhmland B, Heuser T, Kölbl H, Markmann S, Sehouli J.

J Cancer Res Clin Oncol. 2012 Aug;138(8):1413-9. doi: 10.1007/s00432-012-1221-3. Epub 2012 Apr 15.

24.
25.

Single-Incision Slings (SIS) - a New Option for the Surgical Treatment of Female Stress Urinary Incontinence.

Naumann G, Albrich S, Skala C, Laterza R, Kölbl H.

Geburtshilfe Frauenheilkd. 2012 Feb;72(2):125-131.

26.

p53 is correlated with low BMI negative progesterone receptor status and recurring disease in patients with endometrial cancer.

Seeger A, Kölbl H, Petry IB, Gebhard S, Battista MJ, Böhm D, Steiner E.

Gynecol Oncol. 2012 Apr;125(1):200-7. doi: 10.1016/j.ygyno.2011.12.443. Epub 2011 Dec 28.

PMID:
22210468
27.

Prospective randomized comparison of conventional instruments and the Harmonic Focus(®) device in breast-conserving therapy for primary breast cancer.

Böhm D, Kubitza A, Lebrecht A, Schmidt M, Gerhold-Ay A, Battista M, Stewen K, Solbach C, Kölbl H.

Eur J Surg Oncol. 2012 Feb;38(2):118-24. doi: 10.1016/j.ejso.2011.11.003. Epub 2011 Dec 5.

PMID:
22152942
28.

Antibody microarray analysis of the serum proteome in primary breast cancer patients.

Böhm D, Keller K, Boehm N, Lebrecht A, Schmidt M, Kölbl H, Grus FH.

Cancer Biol Ther. 2011 Nov 1;12(9):772-9. doi: 10.4161/cbt.12.9.17675. Epub 2011 Nov 1.

PMID:
21885915
29.

[Clinical and economic challenges of moderate preterm babies born between 32+0 and 36+6 weeks of gestation].

Steetskamp J, Puhl AG, Zelazny J, Skala C, Kölbl H, Bahlmann F.

Z Geburtshilfe Neonatol. 2011 Aug;215(4):158-62. doi: 10.1055/s-0031-1275740. Epub 2011 Aug 26. German.

PMID:
21874633
30.

Serum proteome profiling of primary breast cancer indicates a specific biomarker profile.

Böhm D, Keller K, Wehrwein N, Lebrecht A, Schmidt M, Kölbl H, Grus FH.

Oncol Rep. 2011 Nov;26(5):1051-6. doi: 10.3892/or.2011.1420. Epub 2011 Aug 11.

PMID:
21837365
31.

A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M; EP Investigators.

Clin Cancer Res. 2011 Sep 15;17(18):6012-20. doi: 10.1158/1078-0432.CCR-11-0926. Epub 2011 Aug 1.

32.

["War of the slings": when do I do what and which concept will endure?].

Naumann G, Albrich S, Skala C, Kölbl H.

Urologe A. 2011 Jul;50(7):792-7. doi: 10.1007/s00120-011-2607-6. Review. German.

PMID:
21695455
33.

A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer.

Heinemann V, Di Gioia D, Vehling-Kaiser U, Harich HD, Heinrich B, Welt A, Ziske C, Deutsch G, Pihusch R, Kölbl H, Hegewisch-Becker S, Michl M, Stemmler HJ.

Ann Oncol. 2011 Mar;22(3):603-8. doi: 10.1093/annonc/mdq409. Epub 2010 Aug 19.

PMID:
20724574
34.

Overactive bladder: Is there a link to the metabolic syndrome in men?

Kirby MG, Wagg A, Cardozo L, Chapple C, Castro-Diaz D, de Ridder D, Espuna-Pons M, Haab F, Kelleher C, Kölbl H, Milsom I, Van Kerrebroeck P, Vierhout M, Salvatore S, Tubaro A.

Neurourol Urodyn. 2010 Nov;29(8):1360-4. doi: 10.1002/nau.20892. Review.

PMID:
20589717
35.

ERBB2 induces an antiapoptotic expression pattern of Bcl-2 family members in node-negative breast cancer.

Petry IB, Fieber E, Schmidt M, Gehrmann M, Gebhard S, Hermes M, Schormann W, Selinski S, Freis E, Schwender H, Brulport M, Ickstadt K, Rahnenführer J, Maccoux L, West J, Kölbl H, Schuler M, Hengstler JG.

Clin Cancer Res. 2010 Jan 15;16(2):451-60. doi: 10.1158/1078-0432.CCR-09-1617. Epub 2010 Jan 12.

36.

The prognostic value of four interleukin-1 gene polymorphisms in Caucasian women with breast cancer: a multicenter study.

Grimm C, Kantelhardt E, Heinze G, Polterauer S, Zeillinger R, Kölbl H, Reinthaller A, Hefler L.

BMC Cancer. 2009 Mar 6;9:78. doi: 10.1186/1471-2407-9-78.

37.

Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease.

Kalkum G, Macchiella D, Reinke J, Kölbl H, Beck M.

Eur J Obstet Gynecol Reprod Biol. 2009 May;144(1):92-3. doi: 10.1016/j.ejogrb.2009.01.007. Epub 2009 Feb 23. No abstract available.

PMID:
19233535
38.

Overactive Bladder and Continence Guidelines: implementation, inaction or frustration?

Wagg A, Cardozo L, Chapple C, Diaz DC, de Ridder D, Espuna-Pons M, Haab F, Kelleher C, Kolbl H, Milsom I, Van Kerrebroeck P, Vierhout M, Kirby M.

Int J Clin Pract. 2008 Oct;62(10):1588-93. doi: 10.1111/j.1742-1241.2008.01870.x. Review.

PMID:
18822029
39.

The humoral immune system has a key prognostic impact in node-negative breast cancer.

Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kölbl H, Gehrmann M.

Cancer Res. 2008 Jul 1;68(13):5405-13. doi: 10.1158/0008-5472.CAN-07-5206.

40.

Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer.

Laessig D, Stemmler HJ, Vehling-Kaiser U, Fasching PA, Melchert F, Kolbl H, Stauch M, Maubach P, Scharl A, Morack G, Meerpohl H, Weber B, Kalischefski B, Heinemann V.

Oncology. 2007;73(5-6):407-14. doi: 10.1159/000136796. Epub 2008 Jun 2.

PMID:
18515981
41.

Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).

du Bois A, Pfisterer J, Burchardi N, Loibl S, Huober J, Wimberger P, Burges A, Stähle A, Jackisch C, Kölbl H; Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom; Kommission Uterus.

Gynecol Oncol. 2007 Dec;107(3):518-25. Epub 2007 Oct 25.

PMID:
17910981
42.

Diabetes mellitus is a multivariate independent prognostic factor in endometrial carcinoma: a clinicopathologic study on 313 patients.

Steiner E, Plata K, Interthal C, Schmidt M, Faldum A, Hengstler JG, Sakuragi N, Watari H, Yamamoto R, Kölbl H.

Eur J Gynaecol Oncol. 2007;28(2):95-7.

PMID:
17479668
43.

[Urinary incontinence and urodynamics].

Jünemann KP, Palmtag H, Hampel C, Heidler H, Naumann G, Kölbl H, van der Horst C, Schultz-Lampel D.

Urologe A. 2006 Sep;45 Suppl 4:106-21. Review. German.

PMID:
16944079
44.

[Pathoanatomical preparation and reporting for dysplasias and cancers of the cervix uteri: cervical biopsy, conization, radical hysterectomy and exenteration].

Horn LC, Einenkel J, Höckel M, Kölbl H, Kommoss F, Lax SF, Reich O, Riethdorf L, Schmidt D.

Pathologe. 2007 Jul;28(4):249-60. German.

PMID:
16838175
45.

[Operative treatment of genital prolapse of the female: pros and cons of mesh materials].

Naumann G, Kolbl H.

Gynakol Geburtshilfliche Rundsch. 2006;46(3):96-104. Review. German.

PMID:
16778448
46.

[Massive adenomyosis in a patient with uterus septus completus].

Hansen T, Wulgaris S, Siggelkow W, Kölbl H, Kirkpatrick CJ.

Zentralbl Gynakol. 2006 Jun;128(3):153-6. German.

PMID:
16758383
47.

[Plastic reconstructive procedures of vulvar carcinoma: results and complications].

Weikel W, Schmidt M, Steiner E, Knapstein PG, Kölbl H.

Zentralbl Gynakol. 2006 Jun;128(3):143-8. German.

PMID:
16758381
48.

Dephosphorylation of p-ERK1/2 in relation to tumor remission after HER-2 and Raf1 blocking therapy in a conditional mouse tumor model.

Hausherr CK, Schiffer IB, Gebhard S, Banić A, Tanner B, Kolbl H, Thoenes E, Beckers T, Spangenberg C, Prawitt D, Trost T, Zabel B, Oesch F, Hermes M, Hengstler JG.

Mol Carcinog. 2006 May;45(5):302-8.

PMID:
16496387
49.

Dual-plane implant positioning for capsular contracture of the breast in combination with mastopexy.

Siggelkow W, Lebrecht A, Kölbl H, Faridi A.

Arch Gynecol Obstet. 2005 Dec;273(2):79-85. Epub 2005 Jul 14.

PMID:
16021493
50.

A polymorphism at codon 133 of the tumor suppressor RASSF1A is associated with tumorous alteration of the breast.

Schagdarsurengin U, Seidel C, Ulbrich EJ, Kölbl H, Dittmer J, Dammann R.

Int J Oncol. 2005 Jul;27(1):185-91.

PMID:
15942659

Supplemental Content

Support Center